$101MSeries A, 8 October 2025
Funds new labs in New York, a larger R&D team and preclinical programs.
- Amount
- $101M
- Stage
- Series A
- Announced
- 8 October 2025
- Lead
- The Column Group
- Other investors
- DCVC Bio, Lux Capital, Gates Foundation, Alexandria Venture Investments
- Use of funds
- Funds new labs in New York, a larger R&D team and preclinical programs.
- Checked
- Announced by the company
- Sources
- Nilo Therapeutics raises $101M Series A (date approx) aap.com.au
Nilo Therapeutics raises $101M Series A (date approx) news.crunchbase.com